Therefore, validating BRCA1 promoter methylation detection using this technique as a diagnostic and prognostic biomarker has the potential to improve early detection and treatment options, ultimately reducing the morbidity and mortality associated with breast cancer in LMICs. This evidence concerns the gene BRCA1 and breast carcinoma.